Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report

Publisher： Karger

E-ISSN： 1662-6575|3|2|272-276

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.3, Iss.2, 2010-07, pp. : 272-276

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 2, 2014-02 ,pp. : 355-357

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib‐induced psoriasiform eruption in a patient with chronic myeloid leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 467-468

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib Mesylate Resistance in a Chronic Myeloid Leukemia Patient with a Novel e8a2 BCR-ABL Transcript Variant

By  

Acta Haematologica, Vol. 120, Iss. 3, 2008-11 ,pp. : 146-149

Karger

Access to resources Recommend Favorite

Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute

By  

Acta Haematologica, Vol. 128, Iss. 4, 2012-08 ,pp. : 223-232

Karger

Access to resources Recommend Favorite